At its first meeting under the new administration, the US Centers for Disease Control and Prevention’s (CDC) Advisory ...

ACIP votes to expand recommendation for Pfizer’s RSV vaccine Abrysvo to include adults aged 50 to 59 at increased risk of disease: New York Saturday, April 19, 2025, 10:00 Hrs [ ...

US flu activity declined steadily again last week, with rates of influenza-like illness (ILI) dropping further and staying ...

US hospital data from 2018 through 2022 shows carbapenem-resistant Acinetobacter baumanii accounted for more than one third of all Acinetobacter nfections.

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in ...